THE WOODLANDS, Texas,
May 31, 2011 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's
president and chief executive officer, will present at the
Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 10:30 a.m. Eastern Time in New York City. Dr. Sands will provide an
overview on Lexicon's clinical development programs and
milestones.
The Jefferies Global Healthcare Conference will feature
informative presentations from more than 300 leading public and
private healthcare companies across the healthcare services, life
sciences, medical technology, healthcare IT, and biopharmaceuticals
sectors.
A live webcast of the event may be accessed on Lexicon's
corporate website at www.lexpharma.com. An archived version
of the webcast will be available for 30 days after the event on the
company's website.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug candidates in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements,
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained
under "Risk Factors" in Lexicon's annual report on Form 10-K for
the year ended December 31, 2010, as
filed with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.